PIK3CA and melanoma: Due to the technical complexities and laborious efforts required in shRNA approaches for simultaneous knockdown of multiple signaling pathways, previous studies on certain cancer cell lines, including one in melanoma cells [14], only attempted using drug inhibitors for simultaneous suppression of the MAPK and PI3K/Akt pathways.